01—Abstract
Summary
Summary of the 10-K filed February 28, 2008. Cited figures are marked; the original filing is the authoritative source.
Boston Scientific Corporation's (BSX) 2007 10-K filing reveals a year of significant strategic restructuring, marked by sales of non-core businesses and a focus on optimizing operations.
Despite a reported net loss of $495 milliona, the company's net sales grew 7% to $8.36 billion, largely driven by the acquisition of Guidant Corporation, which bolstered its Cardiac Rhythm Management (CRM) segment. However, sales in the crucial coronary stent business saw a notable decline of 19%, primarily due to market concerns surrounding late stent thrombosis and decreased procedural volumes. The company is actively managing its debt, which stood at $8.19 billion at year-end 2007, and is implementing cost-reduction initiatives aimed at improving financial performance and focusing on core growth areas.
The company's strategic initiatives included divesting five non-strategic businesses, leading to approximately 2,000 job reductions. These actions are intended to streamline operations and improve financial flexibility.
Despite the reported net loss, the company's operational cash flow remained positive at $934 millionb, and it continues to invest in research and development, albeit with a strategic realignment to focus on key product lines like drug-eluting stents and CRM technologies. Management is focused on navigating the challenges in the drug-eluting stent market and rebuilding confidence in its CRM offerings while working to resolve outstanding FDA matters.
02—Key points
Key Highlights
- Net sales increased by 7% to $8.36 billion in 2007, primarily driven by the inclusion of Guidant Corporation's results.
- The company reported a net loss of $495 million in 2007, compared to a net loss of $3.577 billion in 2006.
- Coronary stent sales decreased by 19% to $2.03 billion, significantly impacted by market concerns regarding drug-eluting stent safety and a declining market size.
- Cardiac Rhythm Management (CRM) sales increased by 55% to $2.12 billion, reflecting the full year inclusion of Guidant's operations.
- Boston Scientific initiated significant restructuring and cost-reduction measures, including the sale of five non-strategic businesses and approximately 2,300 job reductions.
- Total debt stood at $8.19 billion at year-end 2007, with the company actively working to reduce its debt obligations.
- Cash flow from operations was $934 million in 2007, down from $1.845 billion in 2006.
- The company is addressing FDA warning letters related to quality systems, with reinspections underway, which have impacted product launch schedules.
03—One dollar
Follow one dollar
For each $1.00 of revenue in FY2007, Boston Scientific Corp lost $0.06.
- Revenue$8.36B100.0%
- Cost of revenue−$2.34B28.0%
- Gross profit$6.01B72.0%
- Operating costs−$6.03B72.1%
- Operating income−$14.0M0.2%
- Interest, other & tax−$481.0M5.8%
- Net income−$495.0M5.9%
04—Financials
Financial Highlights
Figures from 10-KFY2007filed February 28, 2008Financial Statements
| Revenue | $8.36B |
| Cost of Revenue | $2.34B |
| Gross Profit | $6.01B |
| SG&A Expenses | $2.91B |
| Operating Expenses | $6.03B |
| Operating Income | -$14.00M |
| Interest Expense | $570.00M |
| Net Income | -$495.00M |
| EPS (Basic) | $-0.33 |
| EPS (Diluted) | $-0.33 |
| Shares Outstanding (Basic) | 1.49B |
| Shares Outstanding (Diluted) | 1.49B |
05—Questions
Frequently Asked Questions
What was the primary driver for the company's revenue growth in 2007?
The primary driver for revenue growth in 2007 was the full-year inclusion of the results from the acquisition of Guidant Corporation, which significantly boosted the Cardiac Rhythm Management (CRM) segment.
What were the main challenges faced by Boston Scientific in 2007?
The company faced significant challenges in the coronary stent market, with sales declining due to concerns about late stent thrombosis and a shrinking market size. Additionally, the company was addressing FDA warning letters related to quality systems, which had impacted product launch schedules and required significant management attention and resources.
How is Boston Scientific addressing its substantial debt load?
Boston Scientific reported total debt of $8.19 billion at the end of 2007. The company is actively working to reduce this debt through strategic initiatives, including the sale of non-core businesses and a focus on generating operating cash flow to pay down obligations. They made significant debt prepayments in early 2008.
What is the outlook for the company's core businesses, particularly drug-eluting stents and CRM?
The company aims to regain market position and physician confidence in its CRM products. For drug-eluting stents, while facing market headwinds, Boston Scientific is investing in next-generation products and leveraging its two-drug-eluting stent platform strategy to maintain leadership, anticipating a market recovery as safety concerns are addressed.
06—Continue